Comparison of the efficacy of Vedolizumab on inflammatory bowel disease in the first and not line treatments
Objective To evaluate the efficacy and safety of Vedolizumab(VDZ)as a first-line biological agent in the treatment of patients with inflammatory bowel disease(IBD).Methods The clinical data of IBD patients treated with VDZ in the First Affiliated Hospital of Air Force Military Medical University from Feb.2021 to May 2022 was ana-lyzed retrospectively.The efficacy of VDZ treatment was compared between patients who have not previously been treated with biological agents group B and who have previously been treated with biological agents(group A).Results A total of 32 patients with IBD treated with VDZ were screened,with group A accounting for 43.8%(14/32)and group B ac-counting for 56.3%(18/32).At 6,14,22 and 52 weeks,there was no statistically significant difference in clinical re-sponse rates between the two groups(all P>0.05).At 22 and 52 weeks,the clinical response rates of group A were higher than those of group B(P<0.05).At 22 and 52 weeks,there was no statistically significant difference in endo-scopic response rates between the two groups(both P>0.05).At 22 weeks,the endoscopic response rate in group A higher than that in group B(P=0.009).During the follow-up period,only one case of allergic rash occurred in group B.Conclusion VDZ as a first-line biological agent,has a good inducing clinical and endoscopic relief effect on IBD in the short term,with high safety.
NETL
NSTL
万方数据
